Sanofi: FDA accepts Dupixent (dupilumab) for review in children with moderate-to-severe asthma finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Paris, France - March 3, 2021 - At its meeting on March 3, 2021, Sanofi's Board of Directors
(2)
- If approved, somatrogon will serve as a once-weekly treatment option -
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for somatrogon, a long-acting recombinant human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD). Pfizer expects a decision from the European Commission in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210226005102/en/ Today s announcement is an example of our decades-long commitment to actively support the pediatric growth hormone deficiency community through therapeutic options that help children reach their full potential, said Brenda Cooperstone, MD, Chief Development Officer, Rare Disease, Pfizer Global Product Development. If approved in the EU, somatrog
Forward-Looking / Cautionary Statements Forward-Looking Statements This presentation, including the oral statements made in connection. | March 2, 2021
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES NEWS RELEASE TNR Gold Announces Close of. | February 28, 2021